NEW YORK--(BUSINESS WIRE)--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. (“Zentalis” or “the Company”) (NASDAQ: ZNTL). Investors who purchased Zentalis securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ZNTL.
Investigation Details
On June 18, 2024, Zentalis informed the market that “the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC).” Following this news, Zentalis stock dropped.
What's Next?
If you are aware of any facts relating to this investigation or purchased Zentalis securities, you can assist this investigation by visiting the firm’s site: bgandg.com/ZNTL. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
